CytoscreenTM
Empower your drug pipeline with high-content, patient derived single-cell sensitivity and resistance imaging.
CytoScreen
Single-cell Functional Precision Medicine
You want to identify potent drug combinations with the potential to demonstrate durable response, but due to lack of patient derived preclinical screening methods, potency is often muted by resistance mechanisms in clinical trials. Anticipating resistance requires better drug treatment assessment; you need to know the true phenotypic response profile for your target indication.
The solution is single-cell functional precision medicine, a technique that rapidly captures treatment response by imaging critical cell subpopulations and phosphoprotein targets in patient derived tumor samples.
Our Platform
Functional Response Across Each Cell, Each Patient, and Each Cohort
CytoScreen is miniaturized single cell imaging approach for evaluating ex vivo combination drug responses in primary patient cells which uses minimal sample requirement, enabling screening of up to 50 drug conditions with less than one million primary cells.
The technology employs the capability to perform digitized molecular counting to quantify surface and intracellular protein targets with precision and exquisite sensitivity. The platform and data analysis software enables new capabilities to assess the functional/pathway status of immune and tumor cell subpopulations and profile the combination therapy effect on multiple protein targets.
Publications and Patents
Real World Clinical Research
Developed and employed at OHSU Knight Cancer Institute, CytoScreen is validated by global experts in field of single cell imaging and oncology translational medicine and supported by prestigious private and government funding organizations.
Publications
William C. Hahn, Tania Q. Vu, Thomas Jacob, Jonathan Weissman et al. An expanded universe of cancer targets. Cell 2021, 184, 1142-1155. Tania Q. Vu et al. Advancing precision medicine combination drug screening: A miniaturized single-cell imaging platform for evaluating immunotherapy-small molecule combination therapeutics in individuals. Clin Cancer Res 2020, 26, (12 Supplement 1), 08. Tania Q. Vu et al. Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting. Sci Rep 2016, 6, 28163.
Patented Technology
CytoImage maintains an exclusive patent license agreement with Oregon Health and Science University enabling intellectual property associate with nanoparticle imaging technology and systems for quantifying cancer cell signaling proteins.
Ready to learn more?
Empower your pipeline
Reach out and an expert consultant will be in touch
